Solicitation of Information and Recommendations for Revising OIG's Provider Self-Disclosure Protocol, 36281-36282 [2012-14585]
Download as PDF
Federal Register / Vol. 77, No. 117 / Monday, June 18, 2012 / Notices
36281
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
FDA 3792 .............................................................................
1 There
9
Average
burden per
response
Total annual
responses
1
9
0.5
(30 minutes)
Total hours
4.5
are no capital costs or operating maintenance costs associated with this collection of information.
Respondents to this proposed
collection of information would be
manufacturers of biosimilar biological
product candidates. Based on FDA’s
database system, there are an estimated
18 manufacturers that fall into this
category. However, not all
manufacturers will have submissions in
a given year and some may have
multiple submissions. FDA estimates 9
annual responses that include the
following: 6 INDs or BPD meetings, 2
applications, and 1 supplement. The
estimated hours per response are based
on FDA’s past experience with other
submissions, which average 30 minutes.
Dated: June 12, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–14740 Filed 6–15–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
[Docket Number OIG–1301–N]
Solicitation of Information and
Recommendations for Revising OIG’s
Provider Self-Disclosure Protocol
Office of Inspector General
(OIG), HHS.
ACTION: Notice and Opportunity for
Comment.
AGENCY:
This Federal Register notice
informs the public that OIG: (1) Intends
to update the Provider Self-Disclosure
Protocol (63 FR 58399, October 30,
1998) and (2) solicits input from the
public for OIG to consider in updating
the Protocol.
DATES: To ensure consideration, public
comments must be delivered to the
address provided below by no later than
5 p.m. on August 17, 2012.
ADDRESSES: In commenting, please refer
to file code OIG–1301–N. Because of
staff and resource limitations, we cannot
accept comments by facsimile (FAX)
transmission.
You may submit comments in one of
three ways (no duplicates, please):
1. Electronically. You may submit
electronic comments on specific
SUMMARY:
mstockstill on DSK4VPTVN1PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Form
VerDate Mar<15>2010
17:02 Jun 15, 2012
Jkt 226001
recommendations and proposals
through the Federal eRulemaking Portal
at https://www.regulations.gov.
2. By regular, express, or overnight
mail. You may send written comments
to the following address: Kenneth D.
Kraft, Office of Inspector General,
Department of Health and Human
Services, Attention: OIG–1301–N, Room
5541B, Cohen Building, 330
Independence Avenue SW.,
Washington, DC 20201. Please allow
sufficient time for mailed comments to
be received before the close of the
comment period.
3. By hand or courier. If you prefer,
you may deliver, by hand or courier,
your written comments before the close
of the comment period to Kenneth D.
Kraft, Office of Inspector General,
Department of Health and Human
Services, Cohen Building, 330
Independence Avenue SW.,
Washington, DC 20201. Because access
to the interior of the Cohen Building is
not readily available to persons without
Federal Government identification,
commenters are encouraged to schedule
their delivery with one of our staff at
(202) 708–9848.
All submissions must include the
agency name and docket number for this
Federal Register document. All
comments, including attachments and
other supporting material received, are
subject to public disclosure.
FOR FURTHER INFORMATION CONTACT:
Kenneth D. Kraft, Department of Health
and Human Services, Office of Inspector
General, Office of External Affairs, at
(202) 708–9848.
SUPPLEMENTARY INFORMATION: Inspection
of Public Comments: All comments
received before the end of the comment
period are available for viewing by the
public. All comments will be posted on
https://www.regulations.gov after they
have been received. Comments received
timely will also be available for public
inspection as they are received at Office
of Inspector General, Department of
Health and Human Services, Cohen
Building, 330 Independence Avenue
SW., Washington, DC 20201, Monday
through Friday of each week from 8:30
a.m. to 4 p.m. To schedule an
appointment to view public comments,
phone (202) 708–9848.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Background: In 1998, OIG published
the Provider Self-Disclosure Protocol
(the Protocol) to establish a process for
health care providers to disclose
potential fraud involving the Federal
health care programs. The Protocol
provides guidance on how to investigate
this conduct, quantify damages, and
report the conduct to OIG to resolve the
provider’s liability exposure under
OIG’s civil money penalty (CMP)
authorities. Over the past 14 years, we
have resolved over 800 disclosures,
resulting in recovering over $280
million to the Federal health care
programs. Through our experience in
resolving Protocol matters, we identified
areas where additional guidance would
be beneficial to the provider community
and would improve the efficient
resolution of Protocol matters.
Specifically, we issued three Open
Letters to Health Care Providers to
address some of these issues. First, in
2006 we announced an initiative to
encourage disclosure of conduct
creating liability under OIG’s antikickback and physician self-referral law
CMP authorities. In 2008, we issued
additional guidance and requirements
for Protocol submissions to increase the
efficiency of the Protocol, including
new requirements for the initial
submission and specific time
commitments from the provider. This
Open Letter also announced the
presumption of not requiring a
compliance agreement as part of settling
a cooperative and complete disclosure.
Finally, in 2009, we stated we would no
longer accept disclosure of a matter into
the Protocol that involved only liability
under the physician self-referral law in
the absence of a colorable anti-kickback
violation. We also announced a
minimum $50,000 settlement amount
for kickback-related submissions.
After over a decade of experience in
resolving Protocol disclosures, we are
considering revising the Protocol to
provide additional guidance. We are
soliciting comments, recommendations,
and other suggestions from concerned
parties and organizations on how best to
revise the Protocol to address relevant
issues and to provide useful guidance to
the health care industry.
E:\FR\FM\18JNN1.SGM
18JNN1
36282
Federal Register / Vol. 77, No. 117 / Monday, June 18, 2012 / Notices
Dated: June 8, 2012.
Daniel R. Levinson,
Inspector General.
[FR Doc. 2012–14585 Filed 6–15–12; 8:45 am]
BILLING CODE 4152–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
mstockstill on DSK4VPTVN1PROD with NOTICES
Endothelial Cell Line To Study
Prevention of Atherosclerosis
Description of Technology:
Atherosclerosis underlies most cases of
cardiovascular disease (CVD), which is
now the major cause of morbidity and
mortality in developed countries. An
inflammatory reaction is an essential
component in the appearance and
development of an atherosclerotic
lesion. The inflammatory process is
associated with the expression of
adhesion molecules such as vascular
cell adhesion molecule (VCAM) at the
surface of endothelial cells.
Antiatherogenic lipoprotein, high
density lipoprotein (HDL), is known to
down regulate the expression of VCAM.
Increasing levels of HDL is a promising
way to reduce the risk of CVD.
This technology is directed to the
generation of a stable endothelial cell
line expressing a luciferase reporter
construct driven by the VCAM
VerDate Mar<15>2010
17:02 Jun 15, 2012
Jkt 226001
promoter. This reporter system enables
an easier measurement of VCAM
expression and determination of the
effect of HDL on endothelial cell
inflammation. This technology can be
used to screen for the effect of drugs that
modulate HDL metabolism and it is
more convenient than doing Western
blots.
Potential Commercial Applications:
• Study of prevention of
atherosclerosis
• Screen serum for the effect of HDL
on endothelial cell inflammation
• Screen for the effect of drugs that
modulate HDL metabolism
Competitive Advantages:
• Easy monitoring of down regulation
of VCAM with luciferase
• More convenient than doing
Western blots
Development Stage: In vitro data
available.
Inventor: Alan T. Remaley (NHLBI).
Publication: D’Souza W, et al.
Structure/function relationships of
apolipoprotein a-I mimetic peptides:
Implications for antiatherogenic
activities of high-density lipoprotein.
Circ Res. 2010 Jul 23;107(2):217–27.
[PMID 20508181].
Intellectual Property: HHS Reference
No. E–149–2012/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301–435–4521;
Fatima.Sayyid@nih.hhs.gov.
Collaborative Research Opportunity:
The Cardiovascular & Pulmonary
Branch, NHLBI/NIH, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize endothelial cells to study
prevention of atherosclerosis. For
collaboration opportunities, please
contact Dr. Alan Remaley at
aremaley1@cc.nih.gov.
Software for Modeling Tumor Delivery
and Penetration of Antibody-Toxin
Anti-Cancer Conjugates
Description of Technology: Available
for licensing is software for modeling
permeability and concentration of
intravenously administered antibody
anti-cancer agent conjugates in solid
tumor. The models can be used to
determine optimal dosing regimen of a
therapeutic in a particular cancer type.
Thirty factors that affect delivery rates
and efficiencies are analyzed as
variables in generating the models.
Potential Commercial Applications:
• Drug Design
• Combination Therapy
• Personalized Medicine
Competitive Advantages:
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
• Accurate permeability modeling of
anti-cancer therapeutics
• Personalized Medicine
Development Stage:
• Early-stage
• Pre-clinical
Inventors: Byungkook Lee (NCI),
Youngshang Pak (EM), Ira Pastan (NCI).
Publications:
1. Fujimori K, et al. A modeling analysis
of monoclonal antibody percolation
through tumors: a binding-site barrier.
J Nucl Med. 1990 Jul;31(7):1191–1198.
[PMID 2362198]
2. Jain RK. Delivery of molecular and
cellular medicine to solid tumors.
Adv Drug Deliv Rev. 2001 Mar
1;46(1–3):149–168. [PMID 11259838]
3. Thurber GM, et al. Antibody tumor
penetration: transport opposed by
systemic and antigen-mediated
clearance. Adv Drug Deliv Rev. 2008
Sep;60(12):1421–1434. [PMID
18541331]
4. Li Y, et al. Delivery of nanomedicines
to extracellular and intracellular
compartments of a solid tumor. Adv
Drug Deliv Rev. 2012 Jan;64(1):29–39.
[PMID 21569804]
5. https://www.accelereyes.com/
examples/drug_delivery_model
6. Pak Y, et al. Antigen shedding may
improve efficiencies for delivery of
antibody-based anticancer agents in
solid tumors. Can Res. 2012 May 4;
Epub ahead of print, doi: 10.1158/
0008–5472.CAN–11–3925. [PMID
22562466]
Intellectual Property: HHS Reference
No. E–060–2012/0—Software. Patent
protection is not being pursued for this
technology.
Licensing Contact: Michael
Shmilovich; 301–435–5019;
mish@codon.nih.gov.
Collaborative Research Opportunity:
The NCI, CCR, Laboratory of Molecular
Biology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize targeted delivery of anticancer agents in solid tumors. For
collaboration opportunities, please
contact John Hewes, Ph.D. at
hewesj@mail.nih.gov.
Mouse Model of STAT5 for the Drug
Screen and the Research of Cancer and
Autoimmunity
Description of Technology: The
invention is a STAT5 mutant mouse
that can be used in research related to
cancer, autoimmunity and infectious
diseases as well as drug screening. The
mouse model itself has multiple
immunological defects resulting in
formation of STAT5 dimers but not
tetramers.
E:\FR\FM\18JNN1.SGM
18JNN1
Agencies
[Federal Register Volume 77, Number 117 (Monday, June 18, 2012)]
[Notices]
[Pages 36281-36282]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-14585]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of Inspector General
[Docket Number OIG-1301-N]
Solicitation of Information and Recommendations for Revising
OIG's Provider Self-Disclosure Protocol
AGENCY: Office of Inspector General (OIG), HHS.
ACTION: Notice and Opportunity for Comment.
-----------------------------------------------------------------------
SUMMARY: This Federal Register notice informs the public that OIG: (1)
Intends to update the Provider Self-Disclosure Protocol (63 FR 58399,
October 30, 1998) and (2) solicits input from the public for OIG to
consider in updating the Protocol.
DATES: To ensure consideration, public comments must be delivered to
the address provided below by no later than 5 p.m. on August 17, 2012.
ADDRESSES: In commenting, please refer to file code OIG-1301-N. Because
of staff and resource limitations, we cannot accept comments by
facsimile (FAX) transmission.
You may submit comments in one of three ways (no duplicates,
please):
1. Electronically. You may submit electronic comments on specific
recommendations and proposals through the Federal eRulemaking Portal at
https://www.regulations.gov.
2. By regular, express, or overnight mail. You may send written
comments to the following address: Kenneth D. Kraft, Office of
Inspector General, Department of Health and Human Services, Attention:
OIG-1301-N, Room 5541B, Cohen Building, 330 Independence Avenue SW.,
Washington, DC 20201. Please allow sufficient time for mailed comments
to be received before the close of the comment period.
3. By hand or courier. If you prefer, you may deliver, by hand or
courier, your written comments before the close of the comment period
to Kenneth D. Kraft, Office of Inspector General, Department of Health
and Human Services, Cohen Building, 330 Independence Avenue SW.,
Washington, DC 20201. Because access to the interior of the Cohen
Building is not readily available to persons without Federal Government
identification, commenters are encouraged to schedule their delivery
with one of our staff at (202) 708-9848.
All submissions must include the agency name and docket number for
this Federal Register document. All comments, including attachments and
other supporting material received, are subject to public disclosure.
FOR FURTHER INFORMATION CONTACT: Kenneth D. Kraft, Department of Health
and Human Services, Office of Inspector General, Office of External
Affairs, at (202) 708-9848.
SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments
received before the end of the comment period are available for viewing
by the public. All comments will be posted on https://www.regulations.gov after they have been received. Comments received
timely will also be available for public inspection as they are
received at Office of Inspector General, Department of Health and Human
Services, Cohen Building, 330 Independence Avenue SW., Washington, DC
20201, Monday through Friday of each week from 8:30 a.m. to 4 p.m. To
schedule an appointment to view public comments, phone (202) 708-9848.
Background: In 1998, OIG published the Provider Self-Disclosure
Protocol (the Protocol) to establish a process for health care
providers to disclose potential fraud involving the Federal health care
programs. The Protocol provides guidance on how to investigate this
conduct, quantify damages, and report the conduct to OIG to resolve the
provider's liability exposure under OIG's civil money penalty (CMP)
authorities. Over the past 14 years, we have resolved over 800
disclosures, resulting in recovering over $280 million to the Federal
health care programs. Through our experience in resolving Protocol
matters, we identified areas where additional guidance would be
beneficial to the provider community and would improve the efficient
resolution of Protocol matters. Specifically, we issued three Open
Letters to Health Care Providers to address some of these issues.
First, in 2006 we announced an initiative to encourage disclosure of
conduct creating liability under OIG's anti-kickback and physician
self-referral law CMP authorities. In 2008, we issued additional
guidance and requirements for Protocol submissions to increase the
efficiency of the Protocol, including new requirements for the initial
submission and specific time commitments from the provider. This Open
Letter also announced the presumption of not requiring a compliance
agreement as part of settling a cooperative and complete disclosure.
Finally, in 2009, we stated we would no longer accept disclosure of a
matter into the Protocol that involved only liability under the
physician self-referral law in the absence of a colorable anti-kickback
violation. We also announced a minimum $50,000 settlement amount for
kickback-related submissions.
After over a decade of experience in resolving Protocol
disclosures, we are considering revising the Protocol to provide
additional guidance. We are soliciting comments, recommendations, and
other suggestions from concerned parties and organizations on how best
to revise the Protocol to address relevant issues and to provide useful
guidance to the health care industry.
[[Page 36282]]
Dated: June 8, 2012.
Daniel R. Levinson,
Inspector General.
[FR Doc. 2012-14585 Filed 6-15-12; 8:45 am]
BILLING CODE 4152-01-P